RISAPS
Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase IIb, non-inferiority proof of principle trial.
1 March 2024
The RISAPS trial is multi-centre, randomised, open-label trial being done to see if high-intensity rivaroxaban is as effective as high-intensity warfarin which is currently a standard treatment for antiphospholipid patients, with or without lupus, who have had a previous stroke, ‘mini stroke’ or other ischemic brain damage.
The Chief Investigator for the RISAPS trial is Professor Hannah Cohen, °×С½ãÂÛ̳H Consultant Haematologist.
This trial is organised by the CCTU at °×С½ãÂÛ̳.
The trial coordination, data collection and analysis and administration will be provided by the CCTU at °×С½ãÂÛ̳.
If you have any questions about this trial you can contact the RISAPS trial manager for further information at email: risaps@ucl.ac.uk.
Trial status:ÌýClosed to recruitment (as of 24 October 2022)
Funder:ÌýVersus Arthritis
ISRCTN:Ìý±õ³§¸é°ä°Õ±·10280992
First patient recruited on: 15 July 2021
Total patients recruited: 43
Ìý